Skip to main content
Fig. 4 | BMC Urology

Fig. 4

From: Expression patterns of the immune checkpoint ligand CD276 in urothelial carcinoma

Fig. 4

Expression of CD276 in normal appearing versus malignant bladder tissue. Paraffin sections of tissue samples from bladder cancer patients of all stages were reacted with anti-CD276 antibody and then counterstained by hematoxylin. The median CD276 expression score was significantly lower in areas surrounding the tumor and appearing healthy (score 50) when compared to the areas confirmed by an expert pathologist as tumor tissue (score 185, p < 0.0001). A considerable scatter of individual CD276 scores was noted in both cohorts

Back to article page